PDLIM7 and non-small cell lung carcinoma: Based on the results, the authors believe that the simultaneous action of DNA-damaging drugs and azithromycin is a promising strategy for the treatment of non-small-cell lung cancer (NSCLC) through the induction of LMP [109].